Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.
The potential of the E5 protein as a tumor vaccine candidate has not been explored yet. In this study, we evaluate the human papillomavirus type 16 (HPV-16) E5 protein delivered by an adenovirus vector as a tumor vaccine for cervical lesions. The results demonstrate that a single intramuscular injection of a recombinant adenovirus carrying the HPV-16 E5 gene into syngeneic animals can reduce the growth of tumors which contain E5 gene expression. Moreover, the E5 vaccine-induced tumor protection occurs through CD8 T cells but not through CD4 T cells in in vitro assays. In addition, our studies using knockout mice with distinct T-cell deficiencies confirm that cytotoxic T-lymphocyte-induced tumor protection is CD8 dependent but CD4 independent. Hence, HPV-16 E5 can be regarded as a tumor rejection antigen.
Liu
D W
DW
Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.
Tsao
Y P
YP
Hsieh
C H
CH
Hsieh
J T
JT
Kung
J T
JT
Chiang
C L
CL
Huang
S J
SJ
Chen
S L
SL
D000256:Adenoviridae; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines; D003602:Cytotoxicity, Immunologic; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology*; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000276:immunology*; D014614:Vaccines, Synthetic; D000086082:Viroporin Proteins
D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D014614:Vaccines, Synthetic; C054859:oncogene protein E5, Human papillomavirus type 16; D000086082:Viroporin Proteins